Table 2.
Current treatments and relevant clinical trials for DCIS
| Trial name | Start year | Participant | Median follow-up (year) | DCIS feature | Control arm | Experimental arm | All new breast events (%) | Status | |
|---|---|---|---|---|---|---|---|---|---|
|
Surgery, radiation therapy |
NSABP B-17 | 1985 | 818 | 10.7 | / | BCS | BCS + RT | 35.1 VS 17.7 | Completed |
| EORTC 10853 | 1986 | 1010 | 10.5 | / | BCS | BCS + RT | 27 VS 15 | Completed | |
| SweDCIS | 1987 | 1067 | 8.0 | / | BCS | BCS + RT | 32 VS 20 | Completed | |
| UK/ANZ DCIS | 1990 | 1701 | 12.7 | / | BCS (±TAM) | BCS + RT (±TAM) | 21.7 VS 9.6 | No longer recruiting | |
| RTOG 9804 | 1999 | 636 | 7.2 | Good risk DCIS | BCS (±TAM) | BCS + RT (±TAM) | 6.7 VS 0.9 | Completed | |
| Endocrine therapy | NSABP B-24 | 1991 | 1804 | 7.0 | ER-positive DCIS | BCS + RT+placebo | BCS + RT + TAM | 31 VS 20 | Completed |
| NSABP B-35 | 2003 | 3104 | 9.0 | HR-positive DCIS | BCS + RT + TAM | BCS + RT + ANA | 7.9 VS 5.8 | Completed | |
| IBIS II DCIS | 2005 | 2980 | 7.2 | HR-positive DCIS | BCS + RT + TAM | BCS + RT + ANA | 5 VS 5 | Completed | |
| Active surveillance | LORIS | 2014 | 181 | / | Low risk DCIS | Surgery | AS | / | No longer recruiting |
| COMET | 2017 | 997 | / | Low risk DCIS | GCC | AS | / | Active, not recruiting | |
| LORD | 2017 | 2500a | / | Low risk DCIS | GCC | AS | / | Recruiting | |
| LORETTA | 2017 | 340a | / |
ER-positive, Low risk DCIS |
/ | TAM alone | / | Recruiting |
DCIS ductal carcinoma in situ, HR hormone receptor, ER estrogen receptor, BCS breast-conserving surgery, RT radiation therapy, TAM tamoxifen, ANA anastrozole, GCC guideline concordant care, AS active surveillance
aEstimated participant